MK-329

Known as: MK 329, MK329 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1989-2011
0102019892011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1992
1992
MK-329, a selective type A cholecystokinin (CCK) receptor antagonist, was given to dogs to test the hypothesis that CCK is one of… (More)
Is this relevant?
1992
1992
MK-329 is a nonpeptidal, highly specific cholecystokinin (CCK) receptor antagonist, with affinity for pancreatic and gallbladder… (More)
Is this relevant?
1992
1992
The ability of the cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, to selectively inhibit 125I-Bolton-Hunter… (More)
Is this relevant?
1992
1992
The role of the vagal and spinal afferent innervation in the inhibition of gastric emptying induced by duodenal perfusion with a… (More)
Is this relevant?
1992
1992
To determine the physiological role of circulating cholecystokinin (CCK), the effect of the CCK receptor antagonist MK-329 on… (More)
Is this relevant?
1991
1991
MK-329 (formerly L-364,718) is a new nonpeptide antagonist for the peripheral (type-A) cholecystokinin (CCK) receptor, which has… (More)
Is this relevant?
1990
1990
Cholecystokinin (CCK) receptor binding was measured in rodent and primate brain and spinal cord using 125I-Bolton Hunter CCK-8… (More)
Is this relevant?
1990
1990
In vitro autoradiography was performed in order to visualize cholecystokinin-A (CCK-A) receptors in sections of Cynomolgus monkey… (More)
Is this relevant?
1990
1990
A cholecystokinin (CCK) receptor antagonist, MK-329, was used to explore the physiological role of CCK in regulating pancreatic… (More)
Is this relevant?
1990
1990
1. Experiments were conducted to determine whether or not the effect of (+)-fenfluramine (3.0 mg kg-1, i.p.) on food intake can… (More)
Is this relevant?